Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05591274 · ClinicalTrials.gov registry record · NA

Virtual Reality Technology for Vasectomy Pain Modulation

A NA study, sponsored by University of Miami.

Terminated
Registry status
NA
Development phase
120
Enrollment target

NCT05591274: Clinical Trial NA study, sponsored by University of Miami.

NCT05591274 is a NA study that was terminated before completion, run by University of Miami. The registered enrollment target is 120 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05591274, a NA study, was terminated before completion, sponsored by University of Miami.

TERMINATED
Registry status
NA
Development phase
120 participants
Enrollment target

Study Summary

This study will evaluate whether or not wearing a virtual reality (VR) headset reduces pain and anxiety in patients undergoing vasectomy. The headset being used is the SmileyScope virtual reality interface, a device already undergoing study for approval by the U.S. Food and Drug Administration (FDA) to reduce pain and anxiety in patients aged 4 years and older undergoing needle blood draw or injection procedures. In this study, the SmileyScope virtual reality interface is considered an investigational device because it is not yet approved for use in adult males undergoing vasectomy.

Primary Outcome

Anxiety will be measured via the State-Trait Anxiety Inventory (STAI) anxiety score \[Range 20-80; 20 = low anxiety, 80 = high anxiety\]

Interventions

  • DEVICE SmileyScope Virtual Reality Headset

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2022-11-17
Est. Completion 2024-03-28
Phase NA
University of Miami

721 total trials

Why NCT05591274 stopped before completion

NCT05591274 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 1 intervention - of which SmileyScope Virtual Reality Headset is the first listed.

NCT05591274 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05591274 about?

NCT05591274 is a clinical study titled "Virtual Reality Technology for Vasectomy Pain Modulation". This study will evaluate whether or not wearing a virtual reality (VR) headset reduces pain and anxiety in patients undergoing vasectomy. The headset being used is the SmileyScope virtual reality interface, a device already undergoing study for approval by the U.S. Food and Drug Administration (FDA)...

What is the current status of trial NCT05591274?

This trial is currently terminated. It is a NA study. The enrollment target is 120 participants. The study started on 2022-11-17. Estimated completion is 2024-03-28.

What interventions are being tested in trial NCT05591274?

The interventions under investigation include: SmileyScope Virtual Reality Headset (DEVICE).

Who is sponsoring clinical trial NCT05591274?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05591274's enrollment target sits among peer trials

120 762nd of 2000 higher than 1,198 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05591274, the US trial registry maintained by the National Library of Medicine. NCT05591274 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.